期刊
EXPERT REVIEW OF HEMATOLOGY
卷 9, 期 1, 页码 79-89出版社
TAYLOR & FRANCIS LTD
DOI: 10.1586/17474086.2016.1112735
关键词
Acute myeloid leukemia; chemotherapy; cost of illness; economic burden; literature review; stem cell transplantation; treatment costs
类别
资金
- American Society of Clinical Oncology (ASCO)
- MDS Clinical Research Consortium
- Celgene Corporation
The economic burden associated with acute myeloid leukemia (AML) is poorly defined and understudied. The goal of this study is estimate the direct cost of illness for AML in the United States (US) and the United Kingdom (UK), by conducting a comprehensive literature review and calculating the average direct cost-of-illness per patient for the first 6months of therapy. Patients were grouped by therapy: intensive chemotherapy alone; induction chemotherapy followed by allogeneic stem cell transplantation (alloSCT); low intensity therapy; and best supportive care. Data suggest that the pathways alloSCT, followed by intensive chemotherapy, are associated with the highest direct costs. Calculated direct costs suggest that they are higher in the US ($14,014 for BSC-only to $352,682 for alloSCT) than in the UK (3708 pound [$5837] for BSC-only to 112,545 pound [$177,187]). AML appears to be associated with significant direct economic costs, but more studies are needed to fully assess the economic impact especially in relation to total and indirect costs.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据